methocarbamol (Rx)

Brand and Other Names:Robaxin
  • Print

Dosing & Uses

AdultPediatricGeriatric

Dosage Forms & Strengths

tablet

  • 500mg
  • 750mg

injectable solution

  • 100mg/mL

Muscle Spasm

1 g IV/IM; additional doses at q8hr until PO; not to exceed 3 g/day

Total parenteral dose SHOULD NOT EXCEED 3 g/day for >3 days, unless treating tetanus; if condition persists, may repeat therapy after drug-free interval of 48 hr

1500 mg PO q6hr for 48-72 hours; not to exceed 8 g/day THEN decrease to 4-4.5 g/day divided q4-8hr

Tetanus

Adjunct therapy: Initial 1-2 g IV injection (at 300 mg/min), THEN

Additional 1-2 g IV infusion for total dose of 3 g initially

May repeat 1-2 g IV q6hr until can give NG or PO

Total of 24 g PO may be needed

Dosing Modifications

Renal failure: Not studied; parenteral dosage form contraindicated due to presence of polyethylene glycol

Hepatic failure: Not studied

Dosage Forms & Strengths

tablet

  • 500mg
  • 750mg

injectable solution

  • 100mg/mL

Tetanus

15 mg/kg/dose IV q6hr PRN or 500 mg/m²/dose; not to exceed 1.8 g/m²/day for 3 days only  

Muscle Spasm

<16 years: Safety and efficacy not established

>16 years: 1500 mg PO q6hr for 48-72 hours; not to exceed 8 g/day THEN decrease to 4-4.5 g/day divided q4-8hr

Considered safe in elderly because of short half-life

Muscle Spasm

500 mg PO q6hr; may gradually titrate dose to response

Next:

Interactions

Interaction Checker

and methocarbamol

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 

            Contraindicated (0)

              Serious - Use Alternative (6)

              • benzhydrocodone/acetaminophen

                benzhydrocodone/acetaminophen, methocarbamol. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.

              • calcium/magnesium/potassium/sodium oxybates

                methocarbamol, calcium/magnesium/potassium/sodium oxybates. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.

              • hydrocodone

                hydrocodone, methocarbamol. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.

              • metoclopramide intranasal

                methocarbamol, metoclopramide intranasal. Either increases effects of the other by Other (see comment). Avoid or Use Alternate Drug. Comment: Avoid use of metoclopramide intranasal or interacting drug, depending on importance of drug to patient.

              • sodium oxybate

                methocarbamol, sodium oxybate. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.

              • sufentanil SL

                sufentanil SL, methocarbamol. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration may result in hypotension, profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.

              Monitor Closely (150)

              • abobotulinumtoxinA

                methocarbamol increases effects of abobotulinumtoxinA by pharmacodynamic synergism. Use Caution/Monitor. Muscle relaxants may enhance botulinum toxin effects. Closely monitor for increased neuromuscular blockade.

              • alfentanil

                methocarbamol and alfentanil both increase sedation. Use Caution/Monitor.

              • alprazolam

                alprazolam and methocarbamol both increase sedation. Use Caution/Monitor.

              • amitriptyline

                methocarbamol and amitriptyline both increase sedation. Use Caution/Monitor.

              • amobarbital

                amobarbital and methocarbamol both increase sedation. Use Caution/Monitor.

              • amoxapine

                methocarbamol and amoxapine both increase sedation. Use Caution/Monitor.

              • apomorphine

                methocarbamol and apomorphine both increase sedation. Use Caution/Monitor.

              • aripiprazole

                methocarbamol and aripiprazole both increase sedation. Use Caution/Monitor.

              • azelastine

                azelastine and methocarbamol both increase sedation. Use Caution/Monitor.

              • baclofen

                baclofen and methocarbamol both increase sedation. Use Caution/Monitor.

              • belladonna and opium

                methocarbamol and belladonna and opium both increase sedation. Use Caution/Monitor.

              • benperidol

                methocarbamol and benperidol both increase sedation. Use Caution/Monitor.

              • benzphetamine

                methocarbamol increases and benzphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • brexanolone

                brexanolone, methocarbamol. Either increases toxicity of the other by sedation. Use Caution/Monitor.

              • brompheniramine

                brompheniramine and methocarbamol both increase sedation. Use Caution/Monitor.

              • buprenorphine

                methocarbamol and buprenorphine both increase sedation. Use Caution/Monitor.

              • buprenorphine buccal

                methocarbamol and buprenorphine buccal both increase sedation. Use Caution/Monitor.

              • buprenorphine, long-acting injection

                buprenorphine, long-acting injection increases effects of methocarbamol by Other (see comment). Modify Therapy/Monitor Closely. Comment: Buprenorphine may enhance the neuromuscular blocking action of skeletal muscle relaxants and increase risk for respiratory depression. Monitor for signs of respiratory depression that may be greater than otherwise expected and decrease muscle relaxant dosage as necessary.

              • butabarbital

                butabarbital and methocarbamol both increase sedation. Use Caution/Monitor.

              • butalbital

                butalbital and methocarbamol both increase sedation. Use Caution/Monitor.

              • butorphanol

                methocarbamol and butorphanol both increase sedation. Use Caution/Monitor.

              • carbinoxamine

                carbinoxamine and methocarbamol both increase sedation. Use Caution/Monitor.

              • carisoprodol

                carisoprodol and methocarbamol both increase sedation. Use Caution/Monitor.

              • chloral hydrate

                chloral hydrate and methocarbamol both increase sedation. Use Caution/Monitor.

              • chlordiazepoxide

                chlordiazepoxide and methocarbamol both increase sedation. Use Caution/Monitor.

              • chlorpheniramine

                chlorpheniramine and methocarbamol both increase sedation. Use Caution/Monitor.

              • chlorpromazine

                methocarbamol and chlorpromazine both increase sedation. Use Caution/Monitor.

              • chlorzoxazone

                chlorzoxazone and methocarbamol both increase sedation. Use Caution/Monitor.

              • cinnarizine

                cinnarizine and methocarbamol both increase sedation. Use Caution/Monitor.

              • clemastine

                clemastine and methocarbamol both increase sedation. Use Caution/Monitor.

              • clobazam

                methocarbamol, clobazam. Other (see comment). Use Caution/Monitor. Comment: Concomitant administration can increase the potential for CNS effects (e.g., increased sedation or respiratory depression).

              • clomipramine

                methocarbamol and clomipramine both increase sedation. Use Caution/Monitor.

              • clonazepam

                clonazepam and methocarbamol both increase sedation. Use Caution/Monitor.

              • clorazepate

                clorazepate and methocarbamol both increase sedation. Use Caution/Monitor.

              • clozapine

                methocarbamol and clozapine both increase sedation. Use Caution/Monitor.

              • codeine

                methocarbamol and codeine both increase sedation. Use Caution/Monitor.

              • cyclizine

                cyclizine and methocarbamol both increase sedation. Use Caution/Monitor.

              • cyclobenzaprine

                cyclobenzaprine and methocarbamol both increase sedation. Use Caution/Monitor.

              • cyproheptadine

                cyproheptadine and methocarbamol both increase sedation. Use Caution/Monitor.

              • dantrolene

                dantrolene and methocarbamol both increase sedation. Use Caution/Monitor.

              • desipramine

                methocarbamol and desipramine both increase sedation. Use Caution/Monitor.

              • dexchlorpheniramine

                dexchlorpheniramine and methocarbamol both increase sedation. Use Caution/Monitor.

              • dexfenfluramine

                methocarbamol increases and dexfenfluramine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • dexmedetomidine

                dexmedetomidine and methocarbamol both increase sedation. Use Caution/Monitor.

              • dextromoramide

                methocarbamol and dextromoramide both increase sedation. Use Caution/Monitor.

              • diamorphine

                methocarbamol and diamorphine both increase sedation. Use Caution/Monitor.

              • diazepam

                diazepam and methocarbamol both increase sedation. Use Caution/Monitor.

              • diazepam intranasal

                diazepam intranasal, methocarbamol. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration may potentiate the CNS-depressant effects of each drug.

              • difenoxin hcl

                methocarbamol and difenoxin hcl both increase sedation. Use Caution/Monitor.

              • dimenhydrinate

                dimenhydrinate and methocarbamol both increase sedation. Use Caution/Monitor.

              • diphenhydramine

                diphenhydramine and methocarbamol both increase sedation. Use Caution/Monitor.

              • diphenoxylate hcl

                methocarbamol and diphenoxylate hcl both increase sedation. Use Caution/Monitor.

              • dipipanone

                methocarbamol and dipipanone both increase sedation. Use Caution/Monitor.

              • dopexamine

                methocarbamol increases and dopexamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • dosulepin

                methocarbamol and dosulepin both increase sedation. Use Caution/Monitor.

              • doxepin

                methocarbamol and doxepin both increase sedation. Use Caution/Monitor.

              • doxylamine

                doxylamine and methocarbamol both increase sedation. Use Caution/Monitor.

              • droperidol

                methocarbamol and droperidol both increase sedation. Use Caution/Monitor.

              • esketamine intranasal

                esketamine intranasal, methocarbamol. Either increases toxicity of the other by sedation. Modify Therapy/Monitor Closely.

              • estazolam

                estazolam and methocarbamol both increase sedation. Use Caution/Monitor.

              • ethanol

                methocarbamol and ethanol both increase sedation. Use Caution/Monitor.

              • etomidate

                etomidate and methocarbamol both increase sedation. Use Caution/Monitor.

              • fenfluramine

                methocarbamol increases and fenfluramine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • fluphenazine

                methocarbamol and fluphenazine both increase sedation. Use Caution/Monitor.

              • flurazepam

                flurazepam and methocarbamol both increase sedation. Use Caution/Monitor.

              • haloperidol

                methocarbamol and haloperidol both increase sedation. Use Caution/Monitor.

              • hydromorphone

                methocarbamol and hydromorphone both increase sedation. Use Caution/Monitor.

              • hydroxyzine

                hydroxyzine and methocarbamol both increase sedation. Use Caution/Monitor.

              • iloperidone

                methocarbamol and iloperidone both increase sedation. Use Caution/Monitor.

              • imipramine

                methocarbamol and imipramine both increase sedation. Use Caution/Monitor.

              • incobotulinumtoxinA

                methocarbamol, incobotulinumtoxinA. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Muscle relaxants may enhance botulinum toxin effects. Closely monitor for increased neuromuscular blockade.

              • ketamine

                ketamine and methocarbamol both increase sedation. Use Caution/Monitor.

              • ketotifen, ophthalmic

                methocarbamol and ketotifen, ophthalmic both increase sedation. Use Caution/Monitor.

              • lasmiditan

                lasmiditan, methocarbamol. Either increases effects of the other by sedation. Use Caution/Monitor. Coadministration of lasmiditan and other CNS depressant drugs, including alcohol have not been evaluated in clinical studies. Lasmiditan may cause sedation, as well as other cognitive and/or neuropsychiatric adverse reactions.

              • lemborexant

                lemborexant, methocarbamol. Either increases effects of the other by sedation. Modify Therapy/Monitor Closely. Dosage adjustment may be necessary if lemborexant is coadministered with other CNS depressants because of potentially additive effects.

              • levorphanol

                methocarbamol and levorphanol both increase sedation. Use Caution/Monitor.

              • lofepramine

                methocarbamol and lofepramine both increase sedation. Use Caution/Monitor.

              • lofexidine

                methocarbamol and lofexidine both increase sedation. Use Caution/Monitor.

              • loprazolam

                loprazolam and methocarbamol both increase sedation. Use Caution/Monitor.

              • lorazepam

                lorazepam and methocarbamol both increase sedation. Use Caution/Monitor.

              • lormetazepam

                lormetazepam and methocarbamol both increase sedation. Use Caution/Monitor.

              • loxapine

                methocarbamol and loxapine both increase sedation. Use Caution/Monitor.

              • loxapine inhaled

                methocarbamol and loxapine inhaled both increase sedation. Use Caution/Monitor.

              • lurasidone

                lurasidone, methocarbamol. Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: Potential for increased CNS depressant effects when used concurrently; monitor for increased adverse effects and toxicity.

              • maprotiline

                methocarbamol and maprotiline both increase sedation. Use Caution/Monitor.

              • marijuana

                methocarbamol and marijuana both increase sedation. Use Caution/Monitor.

              • melatonin

                methocarbamol and melatonin both increase sedation. Use Caution/Monitor.

              • meperidine

                methocarbamol and meperidine both increase sedation. Use Caution/Monitor.

              • meprobamate

                methocarbamol and meprobamate both increase sedation. Use Caution/Monitor.

              • metaxalone

                metaxalone and methocarbamol both increase sedation. Use Caution/Monitor.

              • methadone

                methocarbamol and methadone both increase sedation. Use Caution/Monitor.

              • methylenedioxymethamphetamine

                methocarbamol increases and methylenedioxymethamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • midazolam

                midazolam and methocarbamol both increase sedation. Use Caution/Monitor.

              • midazolam intranasal

                midazolam intranasal, methocarbamol. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Concomitant use of barbiturates, alcohol, or other CNS depressants may increase the risk of hypoventilation, airway obstruction, desaturation, or apnea and may contribute to profound and/or prolonged drug effect.

              • mirtazapine

                methocarbamol and mirtazapine both increase sedation. Use Caution/Monitor.

              • morphine

                methocarbamol and morphine both increase sedation. Use Caution/Monitor.

              • motherwort

                methocarbamol and motherwort both increase sedation. Use Caution/Monitor.

              • moxonidine

                methocarbamol and moxonidine both increase sedation. Use Caution/Monitor.

              • nabilone

                methocarbamol and nabilone both increase sedation. Use Caution/Monitor.

              • nalbuphine

                methocarbamol and nalbuphine both increase sedation. Use Caution/Monitor.

              • nortriptyline

                methocarbamol and nortriptyline both increase sedation. Use Caution/Monitor.

              • olanzapine

                methocarbamol and olanzapine both increase sedation. Use Caution/Monitor.

              • oliceridine

                oliceridine, methocarbamol. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.

                methocarbamol increases toxicity of oliceridine by Other (see comment). Modify Therapy/Monitor Closely. Comment: Anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. Monitor for signs of urinary retention or reduced gastric motility if oliceridine is coadministered with anticholinergics.

              • opium tincture

                methocarbamol and opium tincture both increase sedation. Use Caution/Monitor.

              • orphenadrine

                methocarbamol and orphenadrine both increase sedation. Use Caution/Monitor.

              • oxazepam

                oxazepam and methocarbamol both increase sedation. Use Caution/Monitor.

              • oxycodone

                methocarbamol and oxycodone both increase sedation. Use Caution/Monitor.

              • oxymorphone

                methocarbamol and oxymorphone both increase sedation. Use Caution/Monitor.

              • paliperidone

                methocarbamol and paliperidone both increase sedation. Use Caution/Monitor.

              • papaveretum

                methocarbamol and papaveretum both increase sedation. Use Caution/Monitor.

              • papaverine

                methocarbamol and papaverine both increase sedation. Use Caution/Monitor.

              • pentazocine

                methocarbamol and pentazocine both increase sedation. Use Caution/Monitor.

              • pentobarbital

                pentobarbital and methocarbamol both increase sedation. Use Caution/Monitor.

              • perphenazine

                methocarbamol and perphenazine both increase sedation. Use Caution/Monitor.

              • phenobarbital

                phenobarbital and methocarbamol both increase sedation. Use Caution/Monitor.

              • phenylephrine PO

                methocarbamol increases and phenylephrine PO decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor. .

              • pholcodine

                methocarbamol and pholcodine both increase sedation. Use Caution/Monitor.

              • pimozide

                methocarbamol and pimozide both increase sedation. Use Caution/Monitor.

              • prabotulinumtoxinA

                methocarbamol increases effects of prabotulinumtoxinA by pharmacodynamic synergism. Use Caution/Monitor. Muscle relaxants may enhance botulinum toxin effects. Closely monitor for increased neuromuscular blockade.

              • primidone

                primidone and methocarbamol both increase sedation. Use Caution/Monitor.

              • prochlorperazine

                methocarbamol and prochlorperazine both increase sedation. Use Caution/Monitor.

              • promethazine

                promethazine and methocarbamol both increase sedation. Use Caution/Monitor.

              • propofol

                propofol and methocarbamol both increase sedation. Use Caution/Monitor.

              • propylhexedrine

                methocarbamol increases and propylhexedrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • protriptyline

                methocarbamol and protriptyline both increase sedation. Use Caution/Monitor.

              • quazepam

                quazepam and methocarbamol both increase sedation. Use Caution/Monitor.

              • quetiapine

                methocarbamol and quetiapine both increase sedation. Use Caution/Monitor.

              • ramelteon

                methocarbamol and ramelteon both increase sedation. Use Caution/Monitor.

              • remimazolam

                remimazolam, methocarbamol. Either increases toxicity of the other by sedation. Modify Therapy/Monitor Closely. Coadministration may result in profound sedation, respiratory depression, coma, and/or death. Continuously monitor vital signs during sedation and recovery period if coadministered. Carefully titrate remimazolam dose if administered with opioid analgesics and/or sedative/hypnotics.

              • risperidone

                methocarbamol and risperidone both increase sedation. Use Caution/Monitor.

              • scullcap

                methocarbamol and scullcap both increase sedation. Use Caution/Monitor.

              • secobarbital

                secobarbital and methocarbamol both increase sedation. Use Caution/Monitor.

              • shepherd's purse

                methocarbamol and shepherd's purse both increase sedation. Use Caution/Monitor.

              • stiripentol

                stiripentol, methocarbamol. Either increases effects of the other by sedation. Use Caution/Monitor. Concomitant use stiripentol with other CNS depressants, including alcohol, may increase the risk of sedation and somnolence.

              • sufentanil

                methocarbamol and sufentanil both increase sedation. Use Caution/Monitor.

              • tapentadol

                methocarbamol and tapentadol both increase sedation. Use Caution/Monitor.

              • temazepam

                temazepam and methocarbamol both increase sedation. Use Caution/Monitor.

              • thioridazine

                methocarbamol and thioridazine both increase sedation. Use Caution/Monitor.

              • thiothixene

                methocarbamol and thiothixene both increase sedation. Use Caution/Monitor.

              • topiramate

                methocarbamol and topiramate both increase sedation. Modify Therapy/Monitor Closely.

              • tramadol

                methocarbamol and tramadol both increase sedation. Use Caution/Monitor.

              • trazodone

                methocarbamol and trazodone both increase sedation. Use Caution/Monitor.

              • triazolam

                triazolam and methocarbamol both increase sedation. Use Caution/Monitor.

              • triclofos

                triclofos and methocarbamol both increase sedation. Use Caution/Monitor.

              • trifluoperazine

                methocarbamol and trifluoperazine both increase sedation. Use Caution/Monitor.

              • trimipramine

                methocarbamol and trimipramine both increase sedation. Use Caution/Monitor.

              • xylometazoline

                methocarbamol increases and xylometazoline decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • ziconotide

                methocarbamol and ziconotide both increase sedation. Use Caution/Monitor.

              • ziprasidone

                methocarbamol and ziprasidone both increase sedation. Use Caution/Monitor.

              • zotepine

                methocarbamol and zotepine both increase sedation. Use Caution/Monitor.

              Minor (2)

              • eucalyptus

                methocarbamol and eucalyptus both increase sedation. Minor/Significance Unknown.

              • sage

                methocarbamol and sage both increase sedation. Minor/Significance Unknown.

              Previous
              Next:

              Adverse Effects

              Frequency Not Defined

              Drowsiness

              Dizziness

              Leukopenia (IV)

              Lightheadedness

              Blurred vision

              Headache

              Fever

              Nausea

              Anorexia

              Adynamic ileus

              Dysgeusia

              GI upset

              Nystagmus

              Diplopia

              Flushing

              Vertigo

              Mild muscular incoordination

              Syncope

              Hypotension

              Bradycardia

              Urticaria

              Pruritus

              Rash

              Skin eruptions

              Conjunctivitis with nasal congestion

              Anaphylactic reactions

              Thrombophlebitis (IV)

              Sloughing (IV)

              Injection site pain (IV)

              Hemolysis (IV)

              Increased Hgb and RBCs in urine (IV)

              Seizures (IV)

              Previous
              Next:

              Warnings

              Contraindications

              Hypersensitivity

              Renal impairment (parenteral)

              Cautions

              May cause drowsiness/dizziness; patients should not ingest alcohol or other CNS depressants

              May take with food to avoid stomach upset

              Half-life increases with hepatic impairment

              IV formulation not for use in renal impairment (contains polyethylene glycol; injection rate should not exceed 3 mL/min

              May interfere with screening tests for 5-HIAA and vanillylmandelic acid (VMA)

              Use injection with caution in patients with a history of seizures

              Sedative effects potentiated when used with other sedatives

              Medication is poorly tolerated in the elderly

              Pediatric IV dosing approved only for tetanus

              Previous
              Next:

              Pregnancy & Lactation

              Pregnancy category: C

              Lactation: Not known if excreted in breast milk; use caution

              Pregnancy Categories

              A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

              B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

              C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

              D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

              X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

              NA: Information not available.

              Previous
              Next:

              Pharmacology

              Mechanism of Action

              Unknown; possibly general CNS depression induces skeletal muscle relaxation

              Absorption

              Onset: 30 min

              Peak serum time: 1-2 hr

              Peak plasma concentration: 16.5-29.8 mcg/mL

              Protein binding: 46-50%

              Metabolism

              Liver (dealkylation and hydroxylation)

              Metabolites: Glucuronide and sulfate conjugates of 3-(2-hydroxyphenoxy)-1,2-propanediol-1-carbamate and 3-(4-hydroxy-2-methoxyphenoxy)-1,2-propanediol-1-carbamate; unidentified metabolites

              Elimination

              Half-life: 0.9-1.8 hr

              Excretion: Urine

              Previous
              Next:

              Administration

              IV Administration

              Direct IV: Administer undiluted at not to exceed 3 mL (=300 mg undiluted)/min

              Infusion: Dilute 1 g with up to 250 mL D5W or NS; avoid extravasation, since injection is hypertonic

              Monitor closely for extravasation

              Administer IV while in recumbent position

              Maintain position 15-30 min following infusion

              IM Administration

              Not to exceed 500 mg (5 mL undiluted) should be given into each gluteal region

              Storage

              Injection when diluted to 4 mg/mL in SWI, D5W, or NS is stable for 6 days at room temperature

              Do not refrigerate after dilution

              Previous
              Next:

              Images

              BRAND FORM. UNIT PRICE PILL IMAGE
              methocarbamol oral
              -
              750 mg tablet
              methocarbamol oral
              -
              500 mg tablet
              methocarbamol oral
              -
              750 mg tablet
              methocarbamol oral
              -
              500 mg tablet
              methocarbamol oral
              -
              750 mg tablet
              methocarbamol oral
              -
              500 mg tablet
              methocarbamol oral
              -
              500 mg tablet
              methocarbamol oral
              -
              750 mg tablet
              methocarbamol oral
              -
              750 mg tablet
              methocarbamol oral
              -
              500 mg tablet
              methocarbamol oral
              -
              500 mg tablet
              methocarbamol oral
              -
              500 mg tablet
              methocarbamol oral
              -
              750 mg tablet
              methocarbamol oral
              -
              500 mg tablet
              methocarbamol oral
              -
              750 mg tablet
              methocarbamol oral
              -
              500 mg tablet
              methocarbamol oral
              -
              750 mg tablet
              methocarbamol oral
              -
              750 mg tablet
              Robaxin injection
              -
              100 mg/mL vial
              methocarbamol injection
              -
              100 mg/mL vial
              methocarbamol injection
              -
              100 mg/mL vial
              methocarbamol injection
              -
              100 mg/mL vial
              methocarbamol injection
              -
              100 mg/mL vial
              methocarbamol injection
              -
              100 mg/mL vial
              methocarbamol injection
              -
              100 mg/mL vial
              methocarbamol injection
              -
              100 mg/mL vial
              methocarbamol injection
              -
              100 mg/mL vial
              methocarbamol injection
              -
              100 mg/mL vial
              methocarbamol injection
              -
              100 mg/mL vial

              Copyright © 2010 First DataBank, Inc.

              Previous
              Next:

              Patient Handout

              Select a drug:
              Patient Education
              methocarbamol oral

              METHOCARBAMOL - ORAL

              (meth-oh-KAR-ba-mole)

              COMMON BRAND NAME(S): Robaxin

              USES: Methocarbamol is used to treat muscle spasms/pain. It is usually used along with rest, physical therapy, and other treatment. It works by helping to relax the muscles.

              HOW TO USE: Take this medication by mouth with or without food as directed by your doctor. Do not increase your dose or use this drug more often or for longer than prescribed. Your condition will not improve any faster, and your risk of side effects will increase.The dosage is based on your medical condition and response to treatment.Tell your doctor if your condition does not improve or if it worsens.

              SIDE EFFECTS: Drowsiness, dizziness, lightheadedness, stomach upset, nausea/vomiting, or blurred vision may occur. If any of these effects persist or worsen, tell your doctor or pharmacist promptly.Remember that this medication has been prescribed because your doctor has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.Tell your doctor right away if you have any serious side effects, including: fainting, slow heartbeat, yellowing eyes/skin, persistent nausea/vomiting, mental/mood changes (such as confusion, forgetfulness).A very serious allergic reaction to this drug is rare. However, get medical help right away if you notice any symptoms of a serious allergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist.In the US -Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch.In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.

              PRECAUTIONS: Before taking methocarbamol, tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.Before using this medication, tell your doctor or pharmacist your medical history, especially of: liver disease.This drug may make you dizzy or drowsy or blur your vision. Alcohol or marijuana (cannabis) can make you more dizzy or drowsy. Do not drive, use machinery, or do anything that needs alertness or clear vision until you can do it safely. Avoid alcoholic beverages. Talk to your doctor if you are using marijuana (cannabis).Before having surgery, tell your doctor or dentist about all the products you use (including prescription drugs, nonprescription drugs, and herbal products).Older adults may be more sensitive to the side effects of this drug, especially confusion, dizziness, or drowsiness. These side effects can increase the risk of falling.During pregnancy, this medication should be used only when clearly needed. Discuss the risks and benefits with your doctor.It is unknown if this drug passes into breast milk. Consult your doctor before breast-feeding.

              DRUG INTERACTIONS: Drug interactions may change how your medications work or increase your risk for serious side effects. This document does not contain all possible drug interactions. Keep a list of all the products you use (including prescription/nonprescription drugs and herbal products) and share it with your doctor and pharmacist. Do not start, stop, or change the dosage of any medicines without your doctor's approval.Tell your doctor or pharmacist if you are taking other products that cause drowsiness such as opioid pain or cough relievers (such as codeine, hydrocodone), alcohol, marijuana (cannabis), drugs for sleep or anxiety (such as alprazolam, lorazepam, zolpidem), other muscle relaxants (such as carisoprodol, cyclobenzaprine), or antihistamines (such as cetirizine, diphenhydramine).Check the labels on all your medicines (such as allergy or cough-and-cold products) because they may contain ingredients that cause drowsiness. Ask your pharmacist about using those products safely.This medication may interfere with certain laboratory tests (including VMA or 5-HIAA urine screening test), possibly causing false test results. Make sure laboratory personnel and all your doctors know you use this drug.

              OVERDOSE: If someone has overdosed and has serious symptoms such as passing out or trouble breathing, call 911. Otherwise, call a poison control center right away. US residents can call their local poison control center at 1-800-222-1222. Canada residents can call a provincial poison control center. Symptoms of overdose may include: severe drowsiness/dizziness, seizures, loss of consciousness.

              NOTES: Do not share this medication with others.This medication has been prescribed for your current condition only. Do not use it later for another condition unless your doctor directs you to do so. A different medication may be necessary in that case.

              MISSED DOSE: If you miss a dose, take it as soon as you remember. If it is near the time of the next dose, skip the missed dose. Take your next dose at the regular time. Do not double the dose to catch up.

              STORAGE: Store at room temperature away from light and moisture. Do not store in the bathroom. Keep all medications away from children and pets.Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Properly discard this product when it is expired or no longer needed. Consult your pharmacist or local waste disposal company.

              Information last revised August 2021. Copyright(c) 2021 First Databank, Inc.

              IMPORTANT: HOW TO USE THIS INFORMATION: This is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate for you. This information is not individual medical advice and does not substitute for the advice of your health care professional. Always ask your health care professional for complete information about this product and your specific health needs.

              Previous
              Next:

              Formulary

              FormularyPatient Discounts

              Adding plans allows you to compare formulary status to other drugs in the same class.

              To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

              Adding plans allows you to:

              • View the formulary and any restrictions for each plan.
              • Manage and view all your plans together – even plans in different states.
              • Compare formulary status to other drugs in the same class.
              • Access your plan list on any device – mobile or desktop.

              The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

              Tier Description
              1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
              2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
              3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
              4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
              5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
              6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
              NC NOT COVERED – Drugs that are not covered by the plan.
              Code Definition
              PA Prior Authorization
              Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
              QL Quantity Limits
              Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
              ST Step Therapy
              Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
              OR Other Restrictions
              Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
              Additional Offers
              Email to Patient

              From:

              To:

              The recipient will receive more details and instructions to access this offer.

              By clicking send, you acknowledge that you have permission to email the recipient with this information.

              Email Forms to Patient

              From:

              To:

              The recipient will receive more details and instructions to access this offer.

              By clicking send, you acknowledge that you have permission to email the recipient with this information.

              Previous
              Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.